Latest Breaking News On - அயலா மருந்துகள் - Page 1 : comparemela.com
Investegate |Amryt Pharma plc Announcements | Amryt Pharma plc: Amryt Successfully Completes Acquisition of Chiasma, Inc , Board Appointments, Issues Ordinary Shares and Total Voting Rights
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Benzinga s Top Ratings Upgrades, Downgrades For July 13, 2021
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Is Altisource Portfolio Solutions (ASPS) A Good Investment?
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Israel Biotech Fund (IBF), founded by Dr. David Sidransky, Dr. Yuval Cabilly and Ido Zairi, announced the closing of its second fund with a total of $112 million. The fund will focus on the investment and formation of Israeli biotech and pharma companies developing drugs at different stages of development and for various indications. Amongst the main limited partners of fund II are Harel Insurance, BMS, an international pharmaceutical company, and the CBG fund. The second fund will continue its collaboration with the international advisory team of the fund, which includes, among others, Dr. Sol Barer, founder of Celgene and Chairman of Teva, and Jeff Kindler, former CEO of Pfizer.
Israel Biotech Fund closes $112m second fund
IBF focuses on investments in drug development and medical diagnostics companies in all stages.
Israel Biotech Fund (IBF) has closed its $112 million second fund. The fund was founded by managing partners Dr. David Sidransky, Dr. Yuval Cabilly, and Ido Zairi. The main investors in the second fund include Harel Insurance Investments and Financial Services Ltd. (TASE: HARL), pharmaceutical giant Bristol Myers Squibb (BMS) and the CBG Capital private equity fund.
IBF s second fund is larger than its first fund, which amounted to $70 million, and slightly larger than the amount that it set out to raise.